查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138330

全球腦膜炎球菌疫苗市場 - 2022-2029

Global Meningococcal Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

腦膜炎球菌疫苗的市場驅動力是對腦膜炎球菌疫苗的需求不斷增加和腦膜炎患病率不斷上升。

腦膜炎球菌是腦膜炎的病原體，腦膜炎是一種類似於普通流感的嚴重疾病，以發燒、嘔吐和頭痛為特徵。然後細菌穿過身體並迅速繁殖，最終到達血液、神經和大腦。腦膜炎是一種類似於流感的以發熱、嘔吐和頭痛為特徵的嚴重疾病，腦膜炎的病原體是腦膜炎球菌。然後細菌穿過身體並迅速繁殖，最終到達血液、神經和大腦。開發針對 B 型腦膜炎球菌的疫苗是現代醫學的一個分水嶺。 B 型腦膜炎球菌是美洲、加拿大、歐洲、亞洲和其他幾個地區疾病的主要原因。 2020 年 7 月 1 日，腦膜炎球菌 B 疫苗 (Vexelo) 和腦膜炎球菌 ACWY 疫苗 (Nimenrix) 將被批准用於所有年齡段的患有某些會增加 IMD 風險的醫療條件的人的 NIP。此外，2020 年 4 月 24 日，FDA 批准了用於預防 2 歲及以上人群侵襲性腦膜炎球菌疾病的“MENQADFFY 腦膜炎球菌（A、C、Y、W 組）結合疫苗”批准了生物製劑許可申請。因此，對腦膜炎球菌疫苗的需求增加有望推動市場增長。

與腦膜炎球菌疫苗相關的副作用預計會阻礙市場增長。

大約一半的 MenACWY 疫苗接種者會出現輕微的副作用，例如注射部位發紅、注射部位疼痛、肌肉酸痛和頭痛。 Menomune 疫苗包含四種最常見的腦膜炎球菌菌株。 Menomune 通常會在註射部位引起疼痛、發紅、腫脹、壓痛和腫塊，通常持續 1-2 天。

CDC 報告說，大約一半接受腦膜炎球菌結合疫苗的人在註射部位會出現輕微的副作用，例如發燒、發紅和疼痛。

行業分析

腦膜炎球菌疫苗市場根據各種行業因素（包括未滿足的需求、定價分析、供應鏈分析和監管分析）對市場進行深入分析。

COVID-19 影響分析

在大流行的早期階段，許多國家暫停了疫苗接種計劃，以降低傳播 SARS-CoV-2 的風險。由於 COVID-19，許多疫苗接種計劃將被取消。在許多其他國家，免疫計劃並未停止，但遏制措施減緩了疫苗的接種速度（父母不知道是否正在接種疫苗，學校普遍停課和預約困難）。在八個國家（美國、英國、意大利、法國、德國、阿根廷、巴西和澳大利亞）進行的一項研究發現，在 COVID-19 大流行期間，近一半的父母曾計劃讓孩子患腦膜炎。結果他有推遲或取消他的疫苗接種預約。封鎖限制 (63%) 和對 SARS-CoV-2 傳播的擔憂 (33%) 是此次疫苗接種中斷的主要原因。

全球腦膜炎球菌疫苗市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 預計對腦膜炎球菌疫苗的需求不斷增長將推動市場增長。
    • 限制因素
      • 與腦膜炎球菌疫苗相關的副作用預計會阻礙市場增長。
    • 機會
    • 影響分析

第5章行業分析

  • 波特的五種力量
  • 未滿足的需求
  • 供應鏈
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 結合疫苗
  • 多醣疫苗
  • 聯合疫苗
  • 其他

第 8 章血清分型

  • 男士 ACWY
  • 男裝B/BC
  • 男裝
  • 男士空調
  • 男裝

第 9 章，最終用戶

  • 醫院
  • 診所
  • 疫苗接種中心
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • 賽諾菲巴斯德公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Bio-Manguinhos
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bio-Med Pvt Ltd
  • Serum Institute of India Ltd.
  • Walvax Biotechnology Co., Ltd
  • Incepta Pharmaceuticals Ltd.
  • Chongqing Zhifei Biological Products Co., Ltd.
簡介目錄
Product Code: DMPH1532

Market Overview

Meningococcal Vaccines Market is expected to grow at a high CAGR of 12% during the forecasting period (2022-2029).

Meningococcal vaccines are designed to safeguard against Neisseria meningitidis infection. Vaccines available target certain meningococcus strains such as A, B, C, W-135, and Y. On average, the vaccines provide 80 percent to 100 percent immunity for two years, with some requiring booster doses. The vaccinations could be monovalent, targeting a specific kind of meningococcus, or multivalent.

Market Dynamics

The meningococcal vaccines market factors are the increase in demand for meningococcal vaccines and the increasing prevalence of meningitis.

The increase in demand for meningococcal vaccines is expected to drive market growth.

Meningococcus is the causative agent of meningitis, a severe disease characterized by fever, vomiting, and headache, like the common flu. The bacteria then travel through the body and grow rapidly, eventually reaching the blood, nerves, and brain. Meningococcus is the causative agent of meningitis, a severe disease characterized by fever, vomiting, and headache, similar to the common flu. The bacteria then travel through the body and grow rapidly, eventually reaching the blood, nerves, and brain. Developing a vaccine against meningococcus B is a watershed moment in modern medicine. Meningococcus B is a leading cause of disease in the Americas, Canada, Europe, Asia, and several other regions. On July 1, 2020, the meningococcal B vaccine (Bexsero) and the meningococcal ACWY vaccine (Nimenrix) were funded under the NIP beginning for people of all ages with certain medical conditions that increase their risk of IMD. Furthermore, on April 24, 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older. Hence, increasing demand for meningococcal vaccines is expected to boost the market growth.

The side effects associated with meningococcal vaccines are expected to hamper the market growth.

Approximately half of those who received a MenACWY vaccine experienced mild side effects, such as redness where the shot was administered, soreness in the area where the shot was administered, muscle aches, and headache. Four of the most common types of meningococcal bacteria are included in the menomune vaccine. Menomune commonly causes pain, redness, swelling, tenderness, or a lump at the injection site, usually lasting 1-2 days.

The CDC reports that roughly half of those who receive a meningococcal conjugate vaccine experience mild side effects, such as fever, redness, and pain where the shot was administered.

Industry Analysis

The meningococcal vaccines market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

During the early stages of the pandemic, many countries suspended immunization programs to reduce the risk of spreading SARS-CoV-2. Many vaccination programs are halted due to COVID-19. Although vaccination programs did not cease in many other countries, vaccine uptake slowed due to containment measures (parents were uncertain about whether vaccinations were taking place and experienced difficulties booking appointments with widespread school closures). According to studies conducted in eight countries (the United States, the United Kingdom, Italy, France, Germany, Argentina, Brazil, and Australia), approximately half of parents delayed or canceled a scheduled meningococcal vaccination appointment for their child during the COVID-19 pandemic. The main reasons for this vaccination disruption are lockdown regulations (63%) and concerns about contracting SARS-CoV-2 (33%).

Segment Analysis

The conjugate vaccines segment is expected to hold the largest market share in the meningococcal vaccines market.

Meningococcal conjugate (MenACWY) vaccine protects against four types of Neisseria meningitidis bacteria (serogroups A, C, W, and Y). It is appropriate for all children and teenagers aged 11 and up. Some types of MenACWY are given to younger children (as young as 8 weeks) if they are at a higher risk of contracting meningococcal disease. Conjugate vaccine technology has been used successfully in childhood vaccines to prevent other bacterial meningitis pathogens, such as vaccines against Haemophilus influenzae serotype b (Hib) and, more recently, seven- and nine-valent conjugate pneumococcal vaccines. Meningococcal conjugate vaccines against N. meningitidis serogroup C are highly effective in young children and adolescents, with few side effects.

There are currently four quadrivalent meningococcal conjugate vaccine formulations available globally. All contain MenA, MenC, MenW, and MenY capsular polysaccharides, but the type of carrier protein varies. MenACWY-D (Menactra, Sanofi Pasteur) is conjugated to diphtheria toxoid (D), MenACWY-CRM (Menveo, GSK) is conjugated to CRM, and two MenACWY-TT vaccines, Nimenrix (Pfizer) and the recently available MenQuadfi are conjugated to TT (Sanofi Pasteur). Furthermore, On 24 April 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older.

Geographical Analysis

North American region is expected to hold the largest market share in the global meningococcal vaccines market.

The rising prevalence of meningitis is expected to drive up demand for meningitis vaccines, resulting in rapid market growth. Various pathogens can cause meningitis, but bacterial meningitis has the highest global burden. According to the National Meningitis Association (NMA), approximately 600-1,000 people in the United States contract meningococcal disease each year. Furthermore, preteens, teens, and young adults account for 21% of meningococcal disease cases.

Furthermore, the growing public awareness of the disease is expected to drive market growth in this region. The Meningitis Foundation of America (MFA) is a non-profit organization in the United States dedicated to providing information and support to people with personal experiences with meningitis. This foundation also aims to raise public and medical awareness about the early symptoms of meningitis. As a result, the meningococcal vaccine market is expected to grow steadily over the forecast period.

Competitive Landscape

Major key players in the meningococcal vaccines market are Bio-Manguinhos, Biomed Pvt. Ltd, GlaxoSmithKline PLC, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur Inc., Serum Institute of India Ltd., Walvax Biotechnology Co., Ltd, Incepta Pharmaceuticals Ltd., Chongqing Zhifei Biological Products Co., Ltd.

Sanofi Pasteur Inc.:

Overview:

Sanofi Pasteur is the world's largest company solely dedicated to vaccines. The vaccines division of the French multinational pharmaceutical company Sanofi is known as Sanofi Pasteur. The company's business is divided into pharmaceuticals, chemicals, vaccines, and consumer healthcare.

Product Portfolio:

MenQuadfi is a vaccine given to people aged 2 to help prevent invasive meningococcal disease (including meningitis) caused by the bacterium N meningitides serogroups A, C, W, and Y. Serogroup B disease is not prevented by MenQuadfi.

Key Developments:

On 24 April 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older.

The global meningococcal vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increase in demand for meningococcal vaccines is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The side effects associated with meningococcal vaccines are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Conjugate Vaccines*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Polysaccharide Vaccines
  • 7.4. Combination Vaccines
  • 7.5. Others

8. By Serotype

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 8.1.2. Market Attractiveness Index, By Serotype Segment
  • 8.2. MenACWY*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. MenB/BC
  • 8.4. MenC
  • 8.5. MenAC
  • 8.6. MenA

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Clinics
  • 9.4. Vaccination Centre
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Serotype
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Sanofi Pasteur Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bio-Manguinhos
  • 12.3. GlaxoSmithKline plc
  • 12.4. Merck & Co., Inc.
  • 12.5. Pfizer Inc.
  • 12.6. Bio-Med Pvt Ltd
  • 12.7. Serum Institute of India Ltd.
  • 12.8. Walvax Biotechnology Co., Ltd
  • 12.9. Incepta Pharmaceuticals Ltd.
  • 12.10. Chongqing Zhifei Biological Products Co., Ltd.